In brief
On 3 May 2023, the European Medicines Agency (EMA) launched a public consultation in order to review the rules on the publication of clinical trial information submitted through the Clinical Trials Information System (CTIS). The CTIS is the dedicated web portal for the submission of authorizations relating to clinical trials and their management in Europe, aimed at streamlining clinical trial applications and the supervision of clinical trials pursuant to forth in Regulation (EU) 536/2014.
Key takeaways
The review of the CTIS transparency rules seeks to stimulate the discussion on the best possible approaches to balance clinical trial transparency with confidentiality requirements while simplifying the modalities of use of CTIS to improve user experience and reduce the risk of data breaches.
Following the public consultation, which will end on 28 June 2023, any revision to the transparency rules will be presented to EMA’s Management Board for approval and implementation before the end of 2023.